Loading
One immunotherapy may add years of life in one cancer and weeks in another, yet costs the same. Prices should track the benefit in each use.
Multi-indication oncology drugs are priced at a single level, so payers either overpay for low-value indications or refuse them entirely. Indication-based pricing has been implemented through Italy's AIFA web-based registries and, in effect, through confidential indication-level rebates in some markets; the barrier elsewhere is that claims do not reliably record the indication. The proposal is mandatory indication coding at dispensing (linking the diagnosis code and line of therapy to the drug claim) and indication-level net prices set from value frameworks such as ESMO-MCBS or ICER thresholds.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, European Society for Medical Oncology (ESMO), Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Pembrolizumab.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value, Pembrolizumab.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Pembrolizumab.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value, Pembrolizumab.